Abstract:Chimeric antigen receptor T cell (CAR-T) therapy is a late-model of immune cell therapy that has been shown to be effective in refractory/recurrent B-cell leukemia and lymphoma. Compared with the traditional anti-tumor methods, CAR-T cell therapy has the advantages of higher specificity, stronger lethality and longer-lasting efficacy. Although CAR-T cells have made significant progress in the treatment of hematologic malignancies, diverse difficulties remain in the treatment of solid tumors, including immune escape due to tumor antigen heterogeneity, preventing entry or limiting the persistence of CAR-T cells by physical or cytokine barriers and along with other immunosuppressive molecule and cells in the tumor microenvironment (TME). Otherwise, the intracellular signaling of CAR also impact on CAR-T cells persistence. Appropriate modification of intracellular costimulatory molecular signal in the structure of CAR or coexpression of CAR and cytokines can provide a way to enhance CAR-T cells activity. Additionally, CAR-T cells dysfunction due to T cell exhaustion is associated with multi-factors, especially transcription factors, such as c-Jun, NR4A. Engineering CAR-T cells to coexpress or knockout transcription factors in favor of T<sub>CM</sub> memory CAR-T cells differentiation was proved to prolonged the survival of CAR-T cells. Finally, combination of CAR-T cells with oncolytic viruses, nanoparticles or immune checkpoint inhibitors provides an effective measure to improve CAR-T cells function. Here, we discuss all of these advances and challenges and review promising strategies for treating solid tumors. In particular, we also highlight that CAR-T cells have enormous potential to be used in combination with other immunotherapies.

Progress in Construction of Hypoxia-Sensitive CAR-T Cell for Solid Tumor Therapy

Generation and Functional Verification of Hypoxia-sensitive Chimeric Antigen Receptor-T Cells

Bright future or blind alley? CAR-T cell therapy for solid tumors

Elevating the potential of CAR-T cell therapy in solid tumors: exploiting biomaterials-based delivery techniques

Optimizing CAR-T cell therapy for solid tumors: current challenges and potential strategies

Chimeric-antigen receptor T (CAR-T) cell therapy for solid tumors: challenges and opportunities.

Current challenges and therapeutic advances of CAR-T cell therapy for solid tumors

Rationally designed approaches to augment CAR-T therapy for solid tumor treatment

Advanced Strategies of CAR-T Cell Therapy in Solid Tumors and Hematological Malignancies

The dilemmas and possible solutions for CAR-T cell therapy application in solid tumors

Current progress in CAR-T cell therapy for tumor treatment

Improving the ability of CAR-T cells to hit solid tumors: Challenges and strategies

Enhancing CAR-T cell efficacy in solid tumors by targeting the tumor microenvironment

Recent Progress in Improving the Safety and Efficacy of Chimeric Antigen Receptor T Cell Therapy

Engineering T Cells with Hypoxia-Inducible Chimeric Antigen Receptor (hicar) for Selective Tumor Killing

CAR-T in solid tumors: Blazing a new trail through the brambles

Current Challenges and Strategies for Chimeric Antigen Receptor-T-Cell Therapy for Solid Tumors

New development in CAR-T cell therapy

Advances and Hurdles in CAR T Cell Immune Therapy for Solid Tumors

Novel Strategies to Improve CAR-T Cell Efficacy by Targeting the Solid Tumor Microenvironment

Current Progress in CAR-T Cell Therapy for Solid Tumors